de Abreu Marilda Aparecida Milanez Morgado, Hirata Cleonice Hitomi Watashi, Pimentel Dalva Regina Neto, Weckx Luc Louis Maurice
Stomatology Division, Dermatology Service, Paulista West University, São Paulo, Brazil.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Nov;108(5):714-21. doi: 10.1016/j.tripleo.2009.05.009. Epub 2009 Aug 20.
The aim was to investigate the safety and efficacy of clofazimine for the treatment of recurrent aphthous stomatitis.
In this randomized controlled partially blind study, 23 patients received clofazimine 100 mg daily for 30 days and then 100 mg every other day. Twenty-three patients received colchicine 0.5 mg 3 times daily. Twenty patients received 1 placebo pill 2 times daily. All subjects received medications for 6 months. The chi-squared or Fisher exact tests were used to assess drug efficacy with respect to objective findings and symptoms.
A greater percentage of individuals in the clofazimine group had no further aphthous episodes (17%-44% compared with <or=6% in the other groups). A significantly greater percentage of treatment interruption occurred in the colchicine group because of gastrointestinal effects (23%-45%). Individuals in the clofazimine group who continued to suffer from aphthous stomatitis presented with better results for the evaluated variables.
Clofazimine should be considered for the treatment of recurrent aphthous stomatitis.
旨在研究氯法齐明治疗复发性阿弗他口炎的安全性和有效性。
在这项随机对照半盲研究中，23例患者每日服用氯法齐明100毫克，持续30天，之后隔日服用100毫克。23例患者每日3次服用秋水仙碱0.5毫克。20例患者每日2次服用1粒安慰剂药丸。所有受试者服药6个月。采用卡方检验或Fisher精确检验评估药物在客观发现和症状方面的疗效。
氯法齐明组中无进一步阿弗他发作的个体比例更高（17% - 44%，而其他组为≤6%）。由于胃肠道效应，秋水仙碱组治疗中断的比例显著更高（23% - 45%）。继续患有阿弗他口炎的氯法齐明组个体在评估变量方面表现出更好的结果。
氯法齐明应被考虑用于治疗复发性阿弗他口炎。
